Paul Barsanti - Ideaya Biosciences Chief Officer
| IDYA Stock | USD 26.99 0.21 0.78% |
Executive
Paul Barsanti is Chief Officer of Ideaya Biosciences
| Address | 7000 Shoreline Court, South San Francisco, CA, United States, 94080 |
| Phone | 650 443 6209 |
| Web | https://www.ideayabio.com |
Ideaya Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.1585) % which means that it has lost $0.1585 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.211) %, meaning that it created substantial loss on money invested by shareholders. Ideaya Biosciences' management efficiency ratios could be used to measure how well Ideaya Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -0.18. In addition to that, Return On Capital Employed is expected to decline to -0.23. At present, Ideaya Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 422 M, whereas Non Currrent Assets Other are forecasted to decline to about 416.2 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| RPh Young | Seres Therapeutics | 57 | |
| Bob Lally | Ikena Oncology | N/A | |
| Samuel MD | Tempest Therapeutics | 58 | |
| JD Esq | Seres Therapeutics | 69 | |
| Eddie MBA | Lumos Pharma | N/A | |
| Nicole Esq | HCW Biologics | N/A | |
| Caroline MD | Ikena Oncology | 52 | |
| MD FAAP | Lumos Pharma | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Alexander Constan | Ikena Oncology | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Lee Flowers | HCW Biologics | 78 | |
| Lisa MD | Seres Therapeutics | 65 | |
| Lindsay Young | Tempest Therapeutics | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| David MS | Ikena Oncology | N/A | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.16 |
Ideaya Biosciences Leadership Team
Elected by the shareholders, the Ideaya Biosciences' board of directors comprises two types of representatives: Ideaya Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ideaya. The board's role is to monitor Ideaya Biosciences' management team and ensure that shareholders' interests are well served. Ideaya Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ideaya Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mick OQuigley, Chief Development | ||
| Stu Dorman, Chief Officer | ||
| Paul Stone, CFO VP | ||
| JD Esq, Chief Secretary | ||
| Matthew MD, VP Oncology | ||
| Esq JD, Gen VP | ||
| Yujiro Hata, President, CoFounder | ||
| Michael White, Chief Officer | ||
| Daniel Simon, Chief Officer | ||
| Andres CPA, Senior Officer | ||
| Francine Zelaya, Vice Resources | ||
| Douglas Snyder, Senior Counsel | ||
| Jeffrey Hager, Co Founder | ||
| Paul Barsanti, Chief Officer |
Ideaya Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ideaya Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.16 | ||||
| Operating Margin | (57.31) % | ||||
| Current Valuation | 1.41 B | ||||
| Shares Outstanding | 86.43 M | ||||
| Shares Owned By Insiders | 1.03 % | ||||
| Shares Owned By Institutions | 98.97 % | ||||
| Number Of Shares Shorted | 10.06 M | ||||
| Price To Earning | (2.17) X | ||||
| Price To Book | 1.96 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ideaya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ideaya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ideaya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ideaya Biosciences Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ideaya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ideaya Biosciences. If investors know Ideaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ideaya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.33) | Revenue Per Share 0.051 | Quarterly Revenue Growth (0.03) | Return On Assets (0.16) | Return On Equity (0.21) |
The market value of Ideaya Biosciences is measured differently than its book value, which is the value of Ideaya that is recorded on the company's balance sheet. Investors also form their own opinion of Ideaya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ideaya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ideaya Biosciences' market value can be influenced by many factors that don't directly affect Ideaya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ideaya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ideaya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ideaya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.